AbbVie Inc

4AB

Company Profile

  • Business description

    AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

  • Contact

    1 North Waukegan Road
    North ChicagoIL60064-6400
    USA

    T: +1 847 932-7900

    E: [email protected]

    https://www.abbvie.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    55,000

Stocks News & Analysis

stocks

Why I dislike dividend stocks

If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
stocks

Chart of the Week: Ramsay Health Care margins to rebound

Charts from our latest stock pitch for Ramsay Health Care show a clear path to improved profitability.
stocks

BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs

We plan to raise our fair value estimate of BlackRock stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,375.9019.700.21%
CAC 408,139.2062.200.77%
DAX 4024,152.1429.23-0.12%
Dow JONES (US)46,340.5487.230.19%
FTSE 1009,396.8627.89-0.30%
HKSE25,888.5122.09-0.09%
NASDAQ22,789.64119.560.53%
Nikkei 22548,277.74605.071.27%
NZX 50 Index13,389.1081.700.61%
S&P 5006,689.0017.940.27%
S&P/ASX 2009,068.4018.200.20%
SSE Composite Index3,916.234.020.10%

Market Movers